Feasibility and Acceptibility of a Multi-site Trial of Time Restircted Eating During Chemotheraply for Breast Cancer.

Recruiting now · Not applicable

Conditions studied: Breast Cancer Early Stage Breast Cancer (Stage 1-3), Breast Neoplasm Female, Breast Cancer

In brief

This study is being done to better understand how time restricted eating (eating all food in an 8 hour window) can help a person receiving chemotherapy treatment for breast cancer, stages I-IV. The aim is to find out if time restricted is feasible and acceptable to individuals starting chemotherapy for breast cancer. We will test 3 different eating window options compared to a control group for 24 weeks.

Key facts

Study ID

NCT07387445

Run by

University of Illinois at Chicago

People needed

40

Starts

2026-02-01

Expected to finish

2026-12-31

Last updated by the study team

2026-05-01

Who can join

Age: 25 and older, up to 99. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Age 25-99 at time of consent
• English language or Spanish language (based on availability of lab interpreters)
• ECOG 0 or 1
• Breast cancer to meet histologically confirmed Stage I-III or Stage IV with Medical Oncology approval.
• Demonstrates adequate organ function (absolute neutrophil count ≥ 1,500/μL).
• All screening labs to be obtained within 30 days prior to registration.
• Able to provide written informed consent and HIPAA authorization for release of personal health information, via an approved UIC Institutional Review Board (IRB) informed consent form and HIPAA authorization.
• Women of childbearing potential must not be pregnant or breast-feeding. A negative serum or urine pregnancy test is required per institutional practice guidelines.
• As determined at the discretion of the enrolling physician or protocol designee, ability of the subject to understand and comply with study procedures for the entire length of the study.

You may not qualify if…

• Women with type 1 or insulin dependent type 2 diabetes
• Women with BMI > 45kg/m2 and < 18.5 kg/m2
• Women who are pregnant or nursing. A negative serum or urine pregnancy test is required per institutional practice guidelines.
• Shift workers
• Women with a history of eating disorders
• Enrolled participants with a significant weight loss or weight gain within 3 months of the study (weight gain or loss >4kg)
• Uncontrolled HIV/AIDS or active viral hepatitis
• Any prior malignancy <5 years, chemotherapy within the last year or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of this investigational regimen, as determined by the treating medical oncologist.
• Breast cancer recurrence classified by the treating medical oncologist
• Any mental or medical condition that prevents the patient from giving informed consent or participating in the trial.
• Other major comorbidity, as determined by study PI
• Illicit drug use within previous 3 months or excessive use of alcohol (i.e., > 2 drinks/day)
• Currently participating in Weight Watcher's or another weight loss program, including weight loss medication such as GLP-1 medications.
• Myocardial infarction
• Congestive heart failure
• Chronic hepatitis
• Cirrhosis
• Chronic pancreatitis
• History of solid organ transplantation

Where it is running

• Robert H. Lurie Comprehensive Cancer Center — Chicago, Illinois, United States (enrolling)
• University of Illinois Chicago — Chicago, Illinois, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.